Tag Archives: Another

AstraZeneca rockets toward Tagrisso sales target with another survival win

AstraZeneca already has a Tagrisso approval for patients with previously untreated, EGFR-mutated lung cancer. But it’s shoring up its case with some clutch new data. Friday, the British drugmaker said Tagrisso had beaten out Roche’s rival drug Tarceva and AstraZeneca’s own Iressa at helping patients live longer. The showing came as part of the phase 3 Flaura… Read More »

Viewpoints: Cheaper Drug Imports From Canada Would Be Wonderful But Are Just Another Fantasy; U.S. Needs To Wake Up To Concerns About The Ebola Outbreak

Opinion writers weigh in on these health care topics and others. Los Angeles Times: Trump Comes To His Senses On Prescription Drug Imports President Trump would prefer that you think he’s working tirelessly to protect Americans from soaring drug prices. His administration announced this week it wants to create a system that allows people to… Read More »

J&J’s Darzalex pads blockbuster sales with another myeloma nod in new patients

Johnson & Johnson multiple myeloma drug Darzalex hasn’t stopped rolling since hitting the market. After picking up its first nod in previously untreated patients last May, the drug added a second indication in new patients on Thursday—and its sixth overall. The FDA cleared the product in combination with Celgene’s Revlimid and dexamethasone for patients who… Read More »

Hey, naysayers: Bristol-Myers’ Celgene buy just chalked up another point in its favor

Bristol-Myers Squibb scored more bragging rights for its coming megamerger: The FDA is now officially reviewing one of the “Big 5” Celgene candidates touted as cornerstones of the deal. And it’s ozanimod, the blockbuster MS prospect whose application the FDA wouldn’t even consider last year. Regulators in both the U.S. and Europe accepted Celgene’s ozanimod filings to… Read More »

BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge

Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »